Edge Therapeutics, Inc. (EDGE) At $16.76 Forms Bottom; Enable Midstream Partners, LP (ENBL) Covered By 7 Bullish Analysts Last Week

Among 13 analysts covering Enable Midstream Partners (NYSE:ENBL), 7 have Buy rating, 2 Sell and 4 Hold. Therefore 54% are positive. Enable Midstream Partners had 35 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Enable Midstream Partners, LP (NYSE:ENBL) earned “Neutral” rating by Goldman Sachs on Friday, November 17. The stock of Enable Midstream Partners, LP (NYSE:ENBL) has “Equal-Weight” rating given on Monday, May 9 by Barclays Capital. The stock has “Buy” rating by Citigroup on Monday, October 19. Credit Suisse upgraded Enable Midstream Partners, LP (NYSE:ENBL) on Monday, May 8 to “Outperform” rating. JP Morgan upgraded Enable Midstream Partners, LP (NYSE:ENBL) on Monday, May 23 to “Overweight” rating. The firm has “Underweight” rating by Morgan Stanley given on Thursday, February 25. RBC Capital Markets maintained it with “Hold” rating and $1800 target in Monday, June 5 report. The company was maintained on Sunday, September 17 by RBC Capital Markets. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, September 7. The rating was maintained by Barclays Capital on Friday, February 19 with “Equal-Weight”. See Enable Midstream Partners, LP (NYSE:ENBL) latest ratings:

02/03/2018 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $20 New Target: $19 Maintain
21/02/2018 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $19 New Target: $20 Maintain
06/12/2017 Broker: R. F. Lafferty Rating: Buy New Target: $19.00 Initiate
06/12/2017 Broker: RF Lafferty Rating: Buy New Target: $19 Initiates Coverage On
17/11/2017 Broker: Goldman Sachs Rating: Neutral Reinitiate
22/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $18.0 Maintain

Edge Therapeutics, Inc. (EDGE) formed multiple bottom with $15.59 target or 7.00% below today’s $16.76 share price. Edge Therapeutics, Inc. (EDGE) has $517.37M valuation. The stock increased 1.51% or $0.25 during the last trading session, reaching $16.76. About 47,156 shares traded. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 23.72% since March 21, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Enable Midstream Partners, LP owns, operates, and develops midstream energy infrastructure assets in the United States. The company has market cap of $5.69 billion. It operates in two divisions, Gathering and Processing, and Transportation and Storage. It has a 14.27 P/E ratio. The Gathering and Processing segment provides natural gas gathering, processing, and fractionation services in the Anadarko, Arkoma, and Ark-La-Tex basins, as well as crude oil gathering services in the Bakken Shale formation of the Williston Basin for its producer customers.

The stock increased 0.46% or $0.06 during the last trading session, reaching $13.16. About 353,543 shares traded or 21.43% up from the average. Enable Midstream Partners, LP (NYSE:ENBL) has risen 21.66% since March 21, 2017 and is uptrending. It has outperformed by 4.96% the S&P500.

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics has $34 highest and $18 lowest target. $27.25’s average target is 62.59% above currents $16.76 stock price. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. The stock of Edge Therapeutics, Inc. (NASDAQ:EDGE) has “Outperform” rating given on Monday, May 9 by Credit Suisse. The stock of Edge Therapeutics, Inc. (NASDAQ:EDGE) earned “Outperform” rating by Credit Suisse on Monday, October 26. The firm has “Buy” rating given on Monday, October 26 by Guggenheim. Leerink Swann initiated it with “Outperform” rating and $27 target in Monday, October 26 report. JMP Securities initiated the shares of EDGE in report on Monday, October 26 with “Market Outperform” rating.